Trump favoring cutting off ACA subsidies to insurers

President Donald Trump is reportedly leaning towards ending cost-sharing reduction subsidies, or CSRs, to insurers offering coverage on the Affordable Care Act (ACA) exchanges, which could quickly destabilize the marketplace.

POLITICO reports Trump expressed his desire to end the payments in a May 16 meeting in the Oval Office. While others in the administration, including HHS Secretary Tom Price, MD, are wary of such a move because of the political consequences and how it would discourage insurers from participating in the exchanges, Trump feels the “bold move” would force Democrats in Congress to negotiate a replacement for the ACA, despite party members’ statements otherwise.  

Trump has been encouraged by groups outside the administration to preserve the subsidies. The National Association of Insurance Commissioners has said the ongoing uncertainty around the CSRs could lead many insurers to drop ACA participation in 2018. The attorneys general of 15 states have signed on to intervene in the lawsuit threatening the subsidies. If they are eliminated, a Kaiser Family Foundation study said federal healthcare spending would go up, not down.

Read the full article at the link below: 

""
John Gregory, Senior Writer

John joined TriMed in 2016, focusing on healthcare policy and regulation. After graduating from Columbia College Chicago, he worked at FM News Chicago and Rivet News Radio, and worked on the state government and politics beat for the Illinois Radio Network. Outside of work, you may find him adding to his never-ending graphic novel collection.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.